GlobeNewswire (press release)25, 2013 (GLOBE NEWSWIRE) Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today gave an update on new legislation which provides a framework for accelerated approval of stem cell products in Japan, the world s Mesoblast lifted by Japan stem cell plansCommBank MyWealth all 8 news articles read more
http://blog.zandcell.com/new-japanese-regenerative-medicine-legislation-and-commercial-globenewswire-press-release/?utm_source=rss&utm_medium=rss&utm_campaign=new-japanese-regenerative-medicine-legislation-and-commercial-globenewswire-press-release
Inga kommentarer:
Skicka en kommentar